Cargando…

Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis

OBJECTIVE: To determine the short-term effectiveness safety of baricitinib in children with refractory and/or severe juvenile dermatomyositis (rsJDM) in a real-world setting. METHODS: This was a single-center retrospective study, including 20 children with rsJDM. They were all treated using bariciti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhaoling, Zheng, Qi, Xuan, Wenjie, Xu, Xisheng, Lu, Meiping, Wu, Jianqiang, Zou, Lixia, Xu, Yiping, Xu, Xuefeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530147/ https://www.ncbi.nlm.nih.gov/pubmed/36204670 http://dx.doi.org/10.3389/fped.2022.962585

Ejemplares similares

Case report: Aggressive progression of acute heart failure due to juvenile tuberculosis-associated Takayasu arteritis with aortic stenosis and thrombosis
por: Xuan, Wenjie, et al.
Publicado: (2023)

Efficacy and safety of etanercept biosimilar rhTNFR-Fc in Chinese patients with juvenile idiopathic arthritis: An open-label multicenter observational study
por: Xu, Xuefeng, et al.
Publicado: (2022)

Assessment of Thigh MRI Radiomics and Clinical Characteristics for Assisting in Discrimination of Juvenile Dermatomyositis
por: Hu, Minfei, et al.
Publicado: (2022)

The Vasculopathy of Juvenile Dermatomyositis
por: Papadopoulou, Charalampia, et al.
Publicado: (2018)

Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis
por: Papadopoulou, Charalampia, et al.
Publicado: (2019)

Clinically Amyopathic Juvenile Dermatomyositis
por: Yıldırım, Deniz Gezgin, et al.
Publicado: (2023)

Immunoglobulin-Induced Aseptic Meningitis in Juvenile Dermatomyositis: A Case Report
por: Chan, Oi Man, et al.
Publicado: (2022)

Treatment of refractory juvenile dermatomyositis with tacrolimus
por: Hassan, J, et al.
Publicado: (2008)

Comparison of Children With Onset of Juvenile Dermatomyositis Symptoms Before or After Their Fifth Birthday in a UK and Ireland Juvenile Dermatomyositis Cohort Study
por: Martin, N, et al.
Publicado: (2012)

Juvenile dermatomyositis and nephrotic syndrome: A case report and a mini literature review
por: Zhou, Weiran, et al.
Publicado: (2023)

Clinical nomogram assisting in discrimination of juvenile dermatomyositis-associated interstitial lung disease
por: Hu, Minfei, et al.
Publicado: (2023)

Juvenile dermatomyositis‐associated calcinosis successfully treated with combined immunosuppressive, bisphosphonate, oral baricitinib and physical therapy
por: Agud‐Dios, Manuel, et al.
Publicado: (2022)

Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling
por: Deakin, Claire T., et al.
Publicado: (2018)

Anti–Cytosolic 5′‐Nucleotidase 1A Autoantibodies Are Absent in Juvenile Dermatomyositis
por: Rietveld, Anke, et al.
Publicado: (2021)

Is Anti-NXP2 Autoantibody a Risk Factor for Calcinosis and Poor Outcome in Juvenile Dermatomyositis Patients? Case Series
por: Toplak, Natasa, et al.
Publicado: (2022)

Juvenile Dermatomyositis (JDM) Complicated by Thrombotic Thrombocytopenic Purpura (TTP) and Purtscher's Retinopathy Responsive to Rituximab: Case Report and Literature Review
por: Gullapalli, Keerthi, et al.
Publicado: (2020)

Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China
por: Zhang, Junmei, et al.
Publicado: (2023)

Performance of interferon-gamma levels may lead to earlier diagnosing macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
por: Lu, Meiping, et al.
Publicado: (2023)

Comparison of the Utility and Validity of Three Scoring Tools to Measure Skin Involvement in Patients With Juvenile Dermatomyositis
por: Campanilho‐Marques, Raquel, et al.
Publicado: (2016)

Muscle Biopsy Findings in Combination With Myositis‐Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis
por: Deakin, Claire T., et al.
Publicado: (2016)

Juvenile Dermatomyositis
por: Rhim, Jung Woo
Publicado: (2022)

Effectiveness of anti-TNF-α agents in the treatment of refractory juvenile dermatomyositis
por: Boulter, EL, et al.
Publicado: (2011)

Case report: JAK1/2 inhibition with baricitinib in the treatment of STING-associated vasculopathy with onset in infancy
por: Wu, Jianqiang, et al.
Publicado: (2023)

Etiologic Profile of Older Children With Diffuse Radiological Changes in Eastern China
por: Xu, Xuefeng, et al.
Publicado: (2022)

Juvenile Dermatomyositis in Pregnancy
por: Madu, Anthony Emeka, et al.
Publicado: (2013)

Case Report: Macrophage Activation Syndrome and Widespread Neuroimaging Abnormality in Childhood-Onset Systemic Lupus Erythematosus
por: Shi, Nana, et al.
Publicado: (2021)

Analysis of Published Criteria for Clinically Inactive Disease in a Large Juvenile Dermatomyositis Cohort Shows That Skin Disease Is Underestimated
por: Almeida, Beverley, et al.
Publicado: (2015)

Galectin‐9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation
por: Wienke, Judith, et al.
Publicado: (2019)

Gastroparesis associated with Juvenile Dermatomyositis
por: Martin, N, et al.
Publicado: (2008)

Respiratory involvement in juvenile dermatomyositis
por: Fabi, M, et al.
Publicado: (2008)

Juvenile dermatomyositis in Western Switzerland
por: Enders, F Bellutti, et al.
Publicado: (2011)

Thrombotic microangiopathy in juvenile dermatomyositis
por: Frolenko, A, et al.
Publicado: (2011)

Calcinosis Universalis in Juvenile Dermatomyositis
por: Chung, Chong Hyuk
Publicado: (2020)

Juvenile Dermatomyositis—Clinical Phenotypes
por: Li, Danyang, et al.
Publicado: (2019)

The Significance of Autoantibodies in Juvenile Dermatomyositis
por: Kwiatkowska, Dominika, et al.
Publicado: (2021)

Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy
por: Han, Yuyang, et al.
Publicado: (2022)

Efficacy and safety of baricitinib in patients with refractory alopecia areata
por: Wang, Yuqian, et al.
Publicado: (2022)

Long-term follow-up of autologous hematopoietic stem cell transplantation for refractory juvenile dermatomyositis: a case-series study
por: Zhu, Jia, et al.
Publicado: (2018)

Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children
por: Xie, Jiao, et al.
Publicado: (2023)

Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool for Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis
por: Wienke, Judith, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_phovh0m70ncmtonlvensvtoa6l